Work

MM-364 Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients

Year: 2024

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(24)01673-2

Authors: Matthew Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Anand Rotte, Christopher Heery, David Avigan, Andrzej Jakubowiak, Michael Bishop

Institutions: Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Medical College of Wisconsin, The University of Texas MD Anderson Cancer Center, University of Chicago

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401876369

Cites:

Cited by:

Related to: 10